Could Pharmacist Prescribing Grow In Wake Of Paxlovid Experience?
Executive Summary
US FDA’s decision to allow pharmacists to prescribe Pfizer’s COVID-19 antiviral raises hopes and fears that the idea that could be applied more broadly post-pandemic.
You may also be interested in...
Letting Paxlovid Go: HHS Seeking To Buffer Drug’s Sticker Shock In ‘Cold’ Commercial World
HHS Secretary Becerra challenges the commercial price Pfizer chose for its COVID-19 therapeutic as the government transitions from being the primary US customer for the drug.
Pharmacies Likely To Cease Prescribing COVID-19 Therapeutics With End Of Public Health Emergency
Existing emergency use authorizations to remain in effect and FDA may continue to issue new ones. Pfizer and Merck are moving to transition Paxlovid and Lagevrio to full approval as FDA allows prescribing without a positive COVID test first.
MSD’s Asia Pacific Chief On Lagevrio’s Gains In Clinical Utility Amid Paxlovid Luster
David Peacock, President, Asia Pacific, MSD tells Scrip how Lagevrio has gained dominance in certain parts of the world, though Paxlovid may have received the ‘lion’s share’ of public attention.